Sanofi Share Holder Equity 2010-2024 | SNY
Sanofi share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
- Sanofi share holder equity for the quarter ending December 31, 2024 was $84.249B, a 4.69% increase year-over-year.
- Sanofi share holder equity for 2024 was $84.249B, a 4.69% increase from 2023.
- Sanofi share holder equity for 2023 was $80.472B, a 1.63% increase from 2022.
- Sanofi share holder equity for 2022 was $79.18B, a 3.05% decline from 2021.
Sanofi Annual Share Holder Equity
(Millions of US $) |
| 2024 |
$84,249 |
| 2023 |
$80,472 |
| 2022 |
$79,180 |
| 2021 |
$81,671 |
| 2020 |
$72,133 |
| 2019 |
$66,201 |
| 2018 |
$69,720 |
| 2017 |
$65,849 |
| 2016 |
$63,877 |
| 2015 |
$64,636 |
| 2014 |
$74,797 |
| 2013 |
$75,732 |
| 2012 |
$73,915 |
| 2011 |
$78,539 |
| 2010 |
$70,761 |
| 2009 |
$67,563 |
Sanofi Quarterly Share Holder Equity
(Millions of US $) |
| 2024-12-31 |
$84,249 |
| 2024-09-30 |
|
| 2024-06-30 |
$78,610 |
| 2024-03-31 |
|
| 2023-12-31 |
$80,472 |
| 2023-09-30 |
|
| 2023-06-30 |
$79,541 |
| 2023-03-31 |
|
| 2022-12-31 |
$79,180 |
| 2022-09-30 |
|
| 2022-06-30 |
$75,882 |
| 2022-03-31 |
|
| 2021-09-30 |
|
| 2021-03-31 |
|
| 2020-09-30 |
|
| 2020-03-31 |
|
| 2019-09-30 |
|
| 2019-03-31 |
|
| 2018-03-31 |
|
| 2017-12-31 |
$65,849 |
| 2017-09-30 |
|
| 2017-06-30 |
$63,583 |
| 2017-03-31 |
|
| 2016-12-31 |
$63,877 |
| 2016-09-30 |
|
| 2016-06-30 |
$61,390 |
| 2016-03-31 |
|
| 2015-09-30 |
|
| 2015-06-30 |
$62,803 |
| 2014-06-30 |
$71,014 |
| 2013-06-30 |
$73,385 |
| 2012-06-30 |
$72,421 |
| 2012-03-31 |
$0 |
| 2011-12-31 |
$78,539 |
| 2011-09-30 |
|
| 2011-06-30 |
$75,685 |
| 2011-03-31 |
|
| 2010-12-31 |
$70,761 |
| 2010-09-30 |
|
| 2010-06-30 |
$67,088 |
| 2010-03-31 |
|
| 2009-12-31 |
$67,563 |
| 2009-09-30 |
|
| 2009-06-30 |
$61,000 |
| 2009-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$136.409B |
$44.458B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
